应用SF-36量表评估中轴型SpA患者非甾体抗炎药治疗后生活质量变化

发布时间：2019-03-02 14:52

【摘要】：目的:应用36条简明健康状况调查量表(SF-36量表)评估中轴型脊柱关节炎(中轴型Sp A)患者应用非甾体抗炎药(NSAIDs)治疗后生活质量的变化情况。方法:选择2014年10月~2015年9月在郑州大学第一附属医院确诊为中轴型Sp A的患者120例。均同意使用指定药物及指定量表评估,并签署知情同意书。采用随机、双盲、平行对照的方法,通过单纯随机分组,将120人分为艾瑞昔布组和塞来昔布组,均为每次200 mg,每天2次,治疗3个月。采用中文版SF-36量表评估中轴型Sp A患者NSAIDs治疗前后的生活质量变化情况。分析生活质量和血沉(ESR)、C反应蛋白(CRP)、Bath AS疾病活动指数(BASDAI)、Bath强直性脊柱炎功能指数(BASFI)、加拿大脊柱关节炎研究协会评分(SPARCC)之间的相关性。结果:中轴型Sp A患者116人完成最终评估,4人失访。应用SF36量表评估中轴型Sp A患者NSAIDs治疗3个月前后生活质量变化,两种药物治疗效果的对比差异无统计学意义(P0.05)。总体患者NSAIDs治疗3个月后,生理功能、生理职能、躯体疼痛、总体健康、社会功能、情感职能与治疗前差异有统计学意义(P0.05);活力、精神健康,差异无统计学意义(P0.05)。BASDAI与PF、RP、BP、GH、VT、SF、RE呈正相关(P0.05);BASDAI与MH无明显相关性(P0.05);BASFI与PF、RP、BP、GH、SF、RE、MH呈正相关(P0.05);BASFI与VT无明显相关性(P0.05)。ESR只与SF、RE呈正相关(P0.05);CRP只与SF、MH呈正相关(P0.05);SPARCC只与PF呈正相关(P0.05)。BASDAI、BASFI是影响PF的重要影响因素(P0.05);BASDAI是影响BP、GH、VT、RE的重要影响因素(P0.05);BASFI是影响RP、SF、MH的重要影响因素(P0.05)。结论:非甾体抗炎药能改善中轴型Sp A患者的生活质量,艾瑞昔布和塞来昔布疗效相当;SF-36量表适用于评估中轴型Sp A患者的生活质量。
[Abstract]:Aim: to evaluate the changes of quality of life (QOL) in patients with axial spinal arthritis (SF- 36) treated with non-steroidal anti-inflammatory drug (NSAIDs) (NSAID). Methods: from October 2014 to September 2015, 120 patients with axial Sp A were selected from the first affiliated Hospital of Zhengzhou University. All agreed to use the designated drug and scale evaluation, and signed an informed consent form. A randomized, double-blind, parallel-controlled method was used to divide the two groups into two groups: Ereiclob group and celecoxib group. The two groups were treated twice a day for 3 months at 200 mg, per day. The two groups were divided into two groups: the control group and the celecoxib group. The quality of life (QOL) of axial Sp A patients before and after NSAIDs treatment was evaluated by Chinese version of SF- 36 scale. To analyze the correlation between quality of life (QOL) and erythrocyte sedimentation rate (ESR), C) (CRP), Bath AS disease activity index (BASDAI), Bath), ankylosing spondylitis function index (BASFI), Canadian Spinal Arthritis Research Association score (SPARCC). Results: one hundred and sixteen patients with axial Sp A completed final evaluation and 4 missed follow-up. SF 36 scale was used to evaluate the quality of life (QOL) of axial Sp A patients before and after NSAIDs treatment for 3 months. There was no significant difference between the two drugs (P0.05). After 3 months of NSAIDs treatment, there were significant differences in physiological function, physical pain, general health, social function and emotional function between the two groups (P0.05). There was no significant difference in vitality and mental health (P0.05). There was a positive correlation between BASDAI and PF,RP,BP,GH,VT,SF,RE (P0.05). There was no significant correlation between); BASDAI and MH (P0.05). There was a positive correlation between BASFI and PF,RP,BP,GH,SF,RE,MH (P0.05); BASFI and VT (P0.05). ESR was only positively correlated with SF,RE (P0.05); CRP was only positively correlated with SF,MH (P0.05). SPARCC was only positively correlated with PF (P0.05). BASDAI, BASFI was an important factor affecting PF (P0.05); BASDAI was an important factor affecting BP,GH,VT,RE (P0.05); BASFI is an important factor influencing RP,SF,MH (P0.05). Conclusion: non-steroidal anti-inflammatory drugs can improve the quality of life of patients with axial Sp A, and the efficacy of erracoxib and celecoxib is the same as that of celecoxib, and the SF- 36 scale can be used to evaluate the quality of life of patients with axial Sp A.
【作者单位】：郑州大学第一附属医院河南省高等学校临床医学重点学科开放实验室风湿免疫科;中国人民解放军总医院第一附属(304)医院风湿免疫科;
【基金】：河南省科技厅基础研究项目河南省高等学校重点科研项目计划(No.16A320011)
【分类号】：R593.2

【参考文献】